Items where Author is "Saletti, P."

Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Date | Item Type | Refereed
Jump to: 2015 | 2010 | 2008
Number of items: 6.


Köberle, D. and Betticher, D. C. and von Moos, R. and Dietrich, D. and Brauchli, B. and Baertschi, D. and Matter, K. and Winterhalder, R. and Borner, M. and Anchisi, S. and Moosmann, P. and Kollar, A. and Saletti, P. and Roth, A. and Frueh, M. and Kueng, M. and Popescu, R. A. and Schacher, S. and Hess, V. and Herrmann, R.. (2015) Bevacizumab continuation versus no continuation after first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a randomized phase III non-inferiority trial (SAKK 41/06). Annals of Oncology, 26 (4). pp. 709-714.


Zlobec, I. and Molinari, F. and Kovac, M. and Bihl, M. P. and Altermatt, H. J. and Diebold, J. and Frick, H. and Germer, M. and Horcic, M. and Montani, M. and Singer, G. and Yurtsever, H. and Zettl, A. and Terracciano, L. and Mazzucchelli, L. and Saletti, P. and Frattini, M. and Heinimann, K. and Lugli, A.. (2010) Prognostic and predictive value of TOPK stratified by KRAS and BRAF gene alterations in sporadic, hereditary and metastatic colorectal cancer patients. British journal of cancer, Vol. 102, no. 1. pp. 151-161.


Borner, M. and Koeberle, D. and Von Moos, R. and Saletti, P. and Rauch, D. and Hess, V. and Trojan, A. and Helbling, D. and Pestalozzi, B. and Caspar, C. and Ruhstaller, T. and Roth, A. and Kappeler, A. and Dietrich, D. and Lanz, D. and Mingrone, W. and Swiss, Group for Clinical Cancer Research and Bern, and Switzerland, . (2008) Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer : a randomized phase II trial of the Swiss Group for Clinical Cancer Research SAKK. Annals of oncology, Vol. 19, H. 7. pp. 1288-1292.

Hess, V. and Glimelius, B. and Grawe, P. and Dietrich, D. and Bodoky, G. and Ruhstaller, T. and Bajetta, E. and Saletti, P. and Figer, A. and Scheithauer, W. and Herrmann, R.. (2008) CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial. The Lancet oncology, Vol. 9. pp. 132-138.

Bernhard, J. and Dietrich, D. and Scheithauer, W. and Gerber, D. and Bodoky, G. and Ruhstaller, T. and Glimelius, B. and Bajetta, E. and Schüller, J. and Saletti, P. and Bauer, J. and Figer, A. and Pestalozzi, B. C. and Köhne, C. H. and Mingrone, W. and Stemmer, S. M. and Tàmas, K. and Kornek, G. V. and Koeberle, D. and Herrmann, R. and Central, European Cooperative Oncology Group. (2008) Clinical benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone : a randomized multicenter phase III clinical trial--SAKK 44/00-CECOG/PAN.1.3.001. Journal of clinical oncology, Vol. 26. pp. 3695-3701.

Koeberle, D. and Saletti, P. and Borner, M. and Gerber, D. and Dietrich, D. and Caspar, C. B. and Mingrone, W. and Beretta, K. and Strasser, F. and Ruhstaller, T. and Mora, O. and Herrmann, R. and Swiss, Group for Clinical Cancer Research. (2008) Patient-reported outcomes of patients with advanced biliary tract cancers receiving gemcitabine plus capecitabine : a multicenter, phase II trial of the swiss group for clinical cancer research. Journal of clinical oncology, Vol. 26. pp. 3702-3708.

This list was generated on Thu Feb 20 08:40:10 2020 CET.